Brenner, A., Reardon, D., Wen, P., Fox, P., Huang, S., Muzi, M., . . . Lee, E. (2017). ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY. Neuro Oncol.
Chicago-tyylinen lähdeviittausBrenner, Andrew, David Reardon, Patrick Wen, Peter Fox, Shiliang Huang, Mark Muzi, Yichu Liu, ja Eudocia Lee. "ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY." Neuro Oncol 2017.
MLA-viiteBrenner, Andrew, et al. "ACTR-95. HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY." Neuro Oncol 2017.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.